Evaluation of the histological size of the sentinel lymph node metastases using RT–PCR assay: a rapid tool to estimate the risk of non-sentinel lymph node invasion in patients with breast cancer I. VeysS. MajjajV. Durbecq Preclinical study 25 September 2009 Pages: 599 - 605
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers Isabella CastellanoElena AlliaAnna Sapino Preclinical study 03 February 2010 Pages: 607 - 617
The androgen receptor in breast cancer: learning from the past Michaela J. HigginsAntonio C. Wolff Invited Commentary 31 March 2010 Pages: 619 - 621
Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells Demissew S. MernKarin Hoppe-SeylerBarbara Burwinkel Preclinical study 27 February 2010 Pages: 623 - 633
Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer Marijke WasielewskiAstrid A. OutMieke Schutte Preclinical study 27 February 2010 Pages: 635 - 641
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age Dorina M. van der KolkGeertruida H. de BockJan C. Oosterwijk Preclinical study 04 March 2010 Pages: 643 - 651
Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study Konstantin J. DedesMaria-Angeles Lopez-GarciaJorge S. Reis-Filho Preclinical study 06 March 2010 Pages: 653 - 666
The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS) N. FortunatiM. G. CatalanoG. Boccuzzi Preclinical study 09 March 2010 Pages: 667 - 675
Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma Fangfang LiuLifang CuiLi Fu Preclinical study 09 March 2010 Pages: 677 - 688
Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features Emilia MontagnaVincenzo BagnardiMarco Colleoni Clinical trial 13 July 2010 Pages: 689 - 699
Primary systemic therapy for operable breast cancer patients: the need for the new generation of trial design Ricardo H. AlvarezGabriel N. Hortobagyi Invited Commentary 16 October 2010 Pages: 701 - 705
A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results Lotte E. ElshofEmiel J. Th. RutgersKenneth G.A. Gilhuijs Clinical trial 22 July 2010 Pages: 707 - 715
Additional findings at preoperative MRI: a simple golden rule for a complex problem? Francesco Sardanelli Invited Commentary 29 August 2010 Pages: 717 - 721
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival Sylvia AdamsA. Bapsi ChakravarthySilvia C. Formenti Clinical trial 29 September 2010 Pages: 723 - 732
Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance Xinmin ZhaoXiaofeng XuXichun Hu Clinical trial 30 September 2010 Pages: 733 - 743
Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues Vincent Launay-VacherJoseph GligorovThe Renal Insufficiency and Anticancer Medications (IRMA) Study Group Epidemiology 15 August 2008 Pages: 745 - 753
BRCA1/2 test results impact risk management attitudes, intentions, and uptake Suzanne C. O’NeillHeiddis B. ValdimarsdottirMarc D. Schwartz Epidemiology 10 April 2010 Pages: 755 - 764
RAD51 135G>C polymorphism contributes to breast cancer susceptibility: a meta-analysis involving 26,444 subjects Zhanwei WangHairong DongHaixia Ding Epidemiology 16 April 2010 Pages: 765 - 769
HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case–control studies Su LuZhanwei WangXishan Hao Epidemiology 17 April 2010 Pages: 771 - 778
MTRR A66G polymorphism and breast cancer risk: a meta-analysis Jia HuGuo-Wu ZhouYa-Jie Wang Epidemiology 22 April 2010 Pages: 779 - 784
Haplotype analysis of XRCC1 (at codons 194 and 399) and susceptibility to breast cancer, a meta-analysis of the literatures Mostafa Saadat Epidemiology 17 April 2010 Pages: 785 - 791
Recording of hormone therapy and breast density in breast screening programs: summary and recommendations of the International Cancer Screening Network Brian CoxRachel Ballard-BarbashDiana Miglioretti Epidemiology 23 April 2010 Pages: 793 - 800
Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients E. BastiaannetG. J. LiefersR. G. J. Westendorp Epidemiology 29 April 2010 Pages: 801 - 807
Endothelial nitric oxide synthase (eNOS) 894 G>T polymorphism is associated with breast cancer risk: a meta-analysis Youjin HaoRafael MontielYongsheng Huang Epidemiology 19 March 2010 Pages: 809 - 813
Association between androgen receptor gene CAG repeat polymorphism and breast cancer risk: a meta-analysis YouJin HaoRafael MontielYongSheng Huang Epidemiology 30 April 2010 Pages: 815 - 820
Three polymorphisms in interleukin-1β gene and risk for breast cancer: a meta-analysis Xiaoan LiuZhanwei WangShui Wang Epidemiology 01 May 2010 Pages: 821 - 825
Plasma tea polyphenol levels and subsequent risk of breast cancer among Japanese women: a nested case–control study Motoki IwasakiManami InoueShoichiro Tsugane Epidemiology 04 May 2010 Pages: 827 - 834
A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer Ying LiuMaria PérezDonna B. Jeffe Epidemiology 06 May 2010 Pages: 835 - 844
Breast-conserving therapy after previous irradiation for lymphoma Sonia K. A. NguyenAnne Dagnault Brief Report 22 May 2009 Pages: 845 - 849
More radiotherapy for radiation-induced second malignancies? Silvia Formenti Invited commentary 18 September 2009 Pages: 851 - 852
No evidence for DNA methylation of von Hippel-Lindau ubiquitin ligase complex genes in breast cancer Katie T. HuangAlexander DobrovicStephen B. Fox Brief Report 03 August 2010 Pages: 853 - 856
Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer Yonglan ZhengJing ZhangOlufunmilayo I. Olopade Brief Report 10 August 2010 Pages: 857 - 861
Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer Diana S. M. BuistLinn A. AbrahamFor the Breast Cancer Surveillance Consortium Brief Report 11 August 2010 Pages: 863 - 873
Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report Brunella PilatoSimona De SummaStefania Tommasi Brief Report 21 August 2010 Pages: 875 - 878
Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer Shih-Chung WuFong-Fu ChouKun-Ming Rau Letter to the Editor 19 August 2010 Pages: 879 - 882
Glutathione S-transferase P1 Ile105Val polymorphism and breast cancer risk: convergence and divergence of the two recent meta-analyses Konstantinos P. EconomopoulosTheodoros N. Sergentanis Letter to the Editor 31 August 2010 Pages: 883 - 887
